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Abstract
Background:  Multiple Endocrine Neoplasia type 1 (MEN1, OMIM 131100) is an autosomal
dominant disorder characterized by endocrine tumors of the parathyroids, pancreatic islets and
pituitary. The disease is caused by the functional loss of the tumor suppressor protein menin, coded
by the MEN1 gene. The protein sequence has no significant homology to known consensus motifs.
In vitro studies have shown menin binding to JunD, Pem, Smad3, NF-kappaB, nm23H1, and RPA2
proteins. However, none of these binding studies have led to a convincing theory of how loss-of-
menin leads to neoplasia.
Results: Global gene expression studies on eight neuroendocrine tumors from MEN1 patients and
4 normal islet controls was performed utilizing Affymetrix U95Av2 chips. Overall hierarchical
clustering placed all tumors in one group separate from the group of normal islets. Within the
group of tumors, those of the same type were mostly clustered together. The clustering analysis
also revealed 19 apoptosis-related genes that were under-expressed in the group of tumors. There
were 193 genes that were increased/decreased by at least 2-fold in the tumors relative to the
normal islets and that had a t-test significance value of p < = 0.005. Forty-five of these genes were
increased and 148 were decreased in the tumors relative to the controls. One hundred and four
of the genes could be classified as being involved in cell growth, cell death, or signal transduction.
The results from 11 genes were selected for validation by quantitative RT-PCR. The average
correlation coefficient was 0.655 (range 0.235–0.964).
Conclusion:  This is the first analysis of global gene expression in MEN1-associated
neuroendocrine tumors. Many genes were identified which were differentially expressed in
neuroendocrine tumors arising in patients with the MEN1 syndrome, as compared with normal
human islet cells. The expression of a group of apoptosis-related genes was significantly suppressed,
suggesting that these genes may play crucial roles in tumorigenesis in this syndrome. We identified
a number of genes which are attractive candidates for further investigation into the mechanisms by
which menin loss causes tumors in pancreatic islets. Of particular interest are: FGF9 which may
stimulate the growth of prostate cancer, brain cancer and endometrium; and IER3 (IEX-1),
PHLDA2 (TSS3), IAPP (amylin), and SST, all of which may play roles in apoptosis.
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Background
Multiple Endocrine Neoplasia type 1 (MEN1, OMIM
131100) is an autosomal dominant disorder character-
ized by endocrine tumors of parathyroid, pancreatic islets
and pituitary [1]. The prevalence of MEN1 is estimated to
be 2–10 per 100,000 [2]. Based on loss of heterozygosity
in tumors and Knudson's "two-hit" hypothesis, the MEN1
gene was classified as a tumor suppressor [2,3] and the
gene was isolated in 1997 by positional cloning [4]. The
MEN1 gene spans 9 kb of the genome, is comprised of 10
exons, and codes for a 610 amino acid protein termed
menin [4]. More than 300 independent germline and
somatic mutations have been identified [5]. Recently, five
new germline mutations which affect splicing of pre-
mRNA transcribed from MEN1 gene were identified in
our laboratory [6]. The nature of all the disease-inducing
mutations points to a loss of function of menin, which is
characteristic of a tumor suppressor. Database analysis of
menin protein sequence reveals no significant homology
to known consensus protein motifs. Menin is widely
expressed in both endocrine and non-endocrine tissues
[4]. Menin is primarily localized in the nucleus and con-
tains two nuclear localization signal sequences near the
carboxyl terminus of the protein [7].
Studies on the function of menin have not yielded a clear
picture as to the role of menin as a tumor suppressor;
however, the results of these studies suggest some interest-
ing possibilities. Two groups [8,9], based on yeast two-
hybrid screening of a human adult brain library, reported
that menin interacts with JunD (a member of the AP-1
transcription factor family) and represses JunD mediated
transcription. Recently, Agarawal et al[10] reported that
when JunD loses its association with menin it becomes a
growth promoter rather than a growth suppressor. Other
reports suggest some relevance of the menin-JunD interac-
tion. JunD null male mice exhibit impaired spermatogen-
esis [11]. In postnatal mouse, Men1  was found to be
expressed in testis (spermatogonia) at high levels [12].
Lemmens et al [13] by screening a 12.5 dpc mouse embryo
library with menin, identified a homeobox-containing
mouse protein, Pem. Interestingly, both menin and Pem
showed a very similar pattern of expression, especially in
testis and Sertoli cells. These findings along with the fact
that some MEN1 patients have idiopathic oligospermia
and non-motility of spermatozoa [14] suggest that menin-
JunD and menin-PEM interactions may play a vital role in
spermatogenesis. Kaji et al [15] observed that menin inter-
acts with Smad3 and inactivation of the former blocks
transforming growth factor beta (TGF-β) signaling in pitu-
itary tumor derived cell lines. Recently, two more menin
interacting proteins, NF-kappa B [16] and a putative
tumor metastasis suppressor nm23 [17] have been identi-
fied. Interactions among AP-1 family members, Smad
proteins and NF-kappa B have been documented [18-21]
and such cross talk among signaling pathways is not
uncommon.
Despite the above studies, a clear consensus of the molec-
ular mechanisms leading to neoplasia, following the loss
of menin, has not emerged. Very little is known about the
gene expression changes in human neuroendocrine
tumors following the loss of menin. Global gene expres-
sion analyses, using cDNA microarrays, have been used to
classify other human tumors into clinically distinct cate-
gories [22-26]. Wu [27] has discussed the mathematical
and statistical considerations for the use of DNA microar-
rays to identify genes of specific interest, and Harkin [28]
has used expression profiling to identify downstream
transcriptional targets of the BRCA1 tumor suppressor
gene. Our objective was to identify genes that might be
directly or indirectly over or under-expressed as a conse-
quence of loss of menin expression.
Results
Patients and Controls
Eight neuroendocrine tumors from six MEN1 patients
were included in this study. The patient ages were 19, 22,
42, 51, 57, and 57 years at the time of surgery (Table 1).
One was female, and five were male. Two of the patients
had clinical and laboratory findings consistent with
insulinoma. Three tumors were analyzed from one of
these patients. One patient had findings consistent with
VIP-oma (vasoactive intestinal polypeptide secreting
tumor). Two patients, with no specific symptoms, had
non-functioning or pancreatic polypeptide secreting
tumors. One patient had symptoms of gastrinoma from a
duodenal tumor (not used for this analysis). A pancreatic
tumor from this patient, found incidentally, was used in
this study. Pathological examination of tumors from the 6
patients resulted in the classification of 3 insulinomas, 3
neuroendocrine tumors, 1 VIP-oma and 1 glucagonoma.
The ages of the individuals donating normal pancreatic
islets were 42, 52(2), and 56 years. Two were female, and
two were male.
Quality of Hybridization
The RNA isolated from 8 tumor specimens (6 patients)
and 4 normal islet preparations was of acceptable quality
for hybridization, as determined by preliminary small
hybridizations on test chips. The dChip computer pro-
gram returned data concerning the percent of genes
judged to be present, and the percent of single and array
outlier events (Table 2). The expression data from one
normal islet preparation had 5.94% array outliers, which
prompted dChip to issue a warning (a warning indicates
more than 5% array outliers detected). However, since we
had only four normal specimens, we elected to include all
four in our analysis. The average level of gene expression
was computed for each gene (Figure 1). The average geneMolecular Cancer 2005, 4:9 http://www.molecular-cancer.com/content/4/1/9
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expression level for all genes followed an exponentially
decreasing pattern; the greatest number of genes had
expression values less than 100, and only a few genes had
expression levels greater than 4000.
Overall Consistency of Gene Expression
Average expression and standard deviation was computed
for each gene in both the group of 4 normal islets, and the
group of 8 islet tumors and expressed as the coefficient of
variation (CV). Genes with average expression levels less
than 50 were excluded from this analysis. Figure 2 shows
that the average (11,416 genes and expressed sequences)
CV in the group of 8 tumors was 30%. There was a linear
regression of CV values as the average minimum expres-
sion level of the genes increased. Genes with an average
minimum expression level of 7000 or more had an aver-
age CV level of 12.7%. The analysis of genes expressed in
the normal islets gave similar results. However, when the
tumors were combined with the normals, the CV was
higher than either group alone. This was caused by the
true differences in gene expression levels between the
tumors and the normals.
Clustering
The experimental groups were clustered (figure 3) using a
hierarchical clustering procedure [29,30]. This cluster was
based on the inclusion of all genes which had 33% to 67%
of "present" calls made by the GeneChip software. The
assignment of tumor type was made on the basis of prin-
cipal hormone messenger RNA levels that were consistent
with the clinical and biochemical findings (Table 3). The
principal bifurcation in the clustering occurred between
the group that included the normal specimens and the
three tumors with a predominance of insulin expression,
on one hand, and the other tumor types on the other. The
four normal islet preparations clustered together, separate
Table 1: Characteristics of patients and normal subjects.
Pt.# T # Age Sex Clinical LN Mets T Vol. (ml) Menin Defect [6]
1 1 19 F Insulinoma 0/1 8.28 Large Deletion, exon 1 & 2
2 2 42 M Neuroendocrine Tumor 0/14 18.75 Nonesense Mutation, exon 7
6 6 60 M VIP-oma 1/16 288 8 bp Deletion, exon 5
7 7 51 M Neuroendocrine Tumor 2/30 3.75 2 bp Deletion, exon 2
8 8–10 22 M Insulinoma 2/8 6.9 2 bp Deletion, exon 2
11 11 57 M Gastrinoma 1/1 0.5 4 bp Deletion, exon 3
N1 N1 52 M Normal NA NA NA
N2 N2 56 F Normal NA NA NA
N3 N3 52 F Normal NA NA NA
N4 N4 42 M Normal NA NA NA
Table 2: Overall statistics on the quality of each the processed GeneChips. One chip was used for each tumor/normal specimen. The 
"Median Intensity" refers to the overall brightness of the fluorescence of the genes. The "Present Call" refers to whether the gene was 
"present" or "absent".
Chip Name Median Intensity Present Call (%) Array outlier % Single outlier % Warning
T1 170 49.4 1.12 0.11
T2 107 46.2 1.54 0.15
T6 160 51.4 1.16 0.12
T7 132 47.7 0.50 0.08
T8 158 51.0 0.59 0.10
T9 114 48.9 0.66 0.10
T10 158 50.6 0.42 0.07
T11 121 46.1 3.34 0.30
N1 142 48.4 2.65 0.26
N2 179 49.7 2.72 0.24
N3 75 48.3 3.38 0.31
N4 73 33.2 9.50 0.63 *Molecular Cancer 2005, 4:9 http://www.molecular-cancer.com/content/4/1/9
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from the tumors. Among the normal islets, the females
clustered separately from the males. Among the tumors,
all 3 insulinomas clustered together, separate from the
VIP-oma, the glucagonoma and the PP-omas (pancreatic
polypeptide producing tumors). It is also interesting that
all the specimens clustered in a pattern of increasing
malignancy going from normal at the bottom of the clus-
ter to most malignant at the top.
The genes were also clustered by the dChip software. A
group of apoptosis-related genes was identified whose
expression was significantly correlated with the Tumor/
Normal assignment of the data. Twenty-four apoptosis-
related genes represented by 26 different Affymetrix
probes were identified in the overall hierarchical cluster-
ing. Nineteen of these genes were more highly expressed
in the normal islets than in the islet tumors (Figure 4).
Eighteen of the nineteen under expressed genes in the set
of tumors had t-test p values (tumor vs. normal) <= 0.037.
All five of the apoptosis-related genes, that were more
highly expressed in the tumors, had t-test p values >0.05
Evaluation of Student's t-test
Since the Student's t-test was designed to compare only
one parameter in two populations, the simultaneous
measurement of multiple genes might lead to an excessive
number of false positives. In order to empirically deter-
mine the potential false positive rate, we started with 923
genes which had a p value <=.05 and repeatedly scram-
bled the individual tests into groups 4 and 8 and then per-
formed new t-tests. The average number of genes having a
p value = < .05 in 20 such scrambles was 51 (5.5% of 923
genes). This was only slightly more than the 46 genes
expected (0.05 × 923). We therefore concluded that there
was little chance of excess false positives in repeatedly
using the Student's t-test.
Hormone Expression Profiles
In order to obtain a better picture of the nature of the
tumors and normal islets in this study, the expression lev-
els of the principal hormone RNA of pancreatic islets was
examined (Table 3). Tumors 1, 8, and 10 had high levels
of insulin expression and came from patients with the
clinical diagnosis of insulinoma. Tumor 6 had high levels
of VIP and came from a patient with the clinical syndrome
of VIP-oma. Tumors 2 and 7 had high levels of pancreatic
polypeptide, and came from patients with only a diagno-
sis of neuroendocrine tumor. Tumor 9, which came from
a patient with a clinical diagnosis of insulinoma had a
high level of glucagon expression; the clinical diagnosis
was apparently due to the other tumor (#8) which did
have a high level of insulin expression. One other appar-
ent discrepancy between the clinical diagnosis and
hormone expression profile occurred with tumor 11,
which had high a level of glucagon expression. This
patient had an additional duodenal tumor that was
responsible for the gastrin secretion and the clinical
diagnosis. All the normal islet preparations had high lev-
els of insulin and glucagon expression, as expected.
Histogram showing the frequency of genes being expressed  at levels between 50 and 7875 (arbitrary expression units) Figure 1
Histogram showing the frequency of genes being expressed 
at levels between 50 and 7875 (arbitrary expression units).
Coefficient of variation (CV) of genes being expressed at lev- els between 50 and 6000 Figure 2
Coefficient of variation (CV) of genes being expressed at lev-
els between 50 and 6000. For each gene expressed at an 
average level of 50 or above, the CV was computed for the 
group of 8 tumors, for the group of 4 normals, and for the 
group of all 12 tumors and normals. As the lower limit of 
expression was increased, the number of genes represented 
in the CV decreased: there were 12,000 genes with expres-
sion levels of 50 or more, but only a few genes with expres-
sion levels of 6,500 or more.
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Comparison of tumor and normal gene expression
The reporting of differentially expressed genes was
restricted to those in which the absolute ratio of Tumor to
Normal was greater than or equal to 2, and which had a
Student's t-test p value of less than or equal to .005. There
were 193 genes that met the criteria. Expressed sequences
with no known protein product were not included. There
were 45 genes that were increased in the tumors relative to
the normals, and 148 genes that were decreased. The fold-
change in expression values ranged from +179 to -449.
Genes were assigned to functional categories based on the
Gene Ontology Consortium assignments http://
www.geneontology.org/. There were 16 genes related to
cell growth, 13 genes related to signal transduction, and
16 genes related to other functions which were increased
in the group of tumors relative to the group of normal
islets (Table 4). There were 44 genes related to cell growth,
10 related to cell death, 10 related to embryogenesis, 5
related to nucleic acid binding, 21 related to cell signaling,
and 58 related to other functions in the group of genes
which were decreased in the islet tumors relative to the
controls (Tables 5, 6, 7, 8).
Validation of GeneChip Data with Quantitative RT-PCR
In order to evaluate how accurately the GeneChip data
was representing actual gene expression levels, eleven
genes were tested with quantitative RT-PCR (Q-PCR). The
results are shown in Table 9. The correlation coefficients
ranged from 0.964 to 0.235 with an average of 0.655. The
lower correlation coefficients were associated with genes
with larger numbers of exons. There was some association
of low correlation with low average numerical expression
values. The lowest correlations were associated with very
faint image intensity of the involved genes in the dChip
visual representation. The correlation coefficients of 4
genes, identified as apoptosis-related, was examined in
detail (Figure 5). IER3, IAPP, SST, and PHLDA2 all had
good correlation between GeneChip and Q-PCR results.
FGF9, a potential growth stimulating gene was also exam-
ined (Figure 6). Again, there was overall good correlation
between the individual GeneChip and Q-PCR results.
Discussion
Whether there were degradative processes acting on the
tissues prior to or during or after the extraction of the RNA
can be guessed by the quality of the RNA. Each RNA
specimen in this study was tested on an Affymetrix test
chip, and each was found to be acceptable. Additional
quality assessment was made by the dChip software. Only
one specimen, a normal control, had Array Outliers
greater than 5%, suggesting that it was subnormal (Table
2). However, since the percent outliers was only 5.94, the
chip was included in the analysis.
Although, only solid tumor was utilized, there were
undoubtedly a small percentage of blood, blood vessel,
and connective tissue elements intermixed with the tumor
tissue. Rarely, there might be a small amount of exocrine
Table 3: Gene expression levels of islet hormone mRNAs in tumors and normals. VIP: Vasoactive intestinal polypeptide; PP: 
Pancreatic polypeptide.
T1 T2 T6 T7 T8 T9 T10 T11 N1 N2 N3 N4
pre-Gastrin 864 530 678 392 600 383 209 395 1036 775 28 1192
Insulin 9990 13 179 401 10195 240 8971 1831 10010 9752 9580 8158
Glucagon 10 6482 2783 1198 10 8370 10 10 9037 8425 9043 7800
VIP 351 278 10243 374 334 276 362 202 806 436 334 389
PP 246 7257 577 5845 70 1805 211 8895 1897 7605 3598 1177
Clustering of tumors and normals according to overall gene  expression patterns Figure 3
Clustering of tumors and normals according to overall gene 
expression patterns. The predominant type of hormone 
expression (Table 3) is noted for each tumor/normal 
specimen.
T6 Vasoactive Intestinal Polypeptide…
T2 Pancreatic Polypeptide………………
T9 Glucagon ………………………………
T7 Pancreatic Polypeptide………………
T11 Pancreatic Polypeptide…………….
T1 Insulin…………………………………...
T8 Insulin…………………………………...
T10 Insulin………………………………….
N2 Normal Female………………………..
N3 Normal Female………………………...
N1 Normal Male……………………………
N4 Normal Male……………………………Molecular Cancer 2005, 4:9 http://www.molecular-cancer.com/content/4/1/9
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Clustering of apoptosis-related genes in tumors (T) and normals (N) Figure 4
Clustering of apoptosis-related genes in tumors (T) and normals (N). Pink indicates strong, white indicates moderate, and blue 
indicates weak expression.
Seven in absentia homolog 1
Fas (TNFRSF6)-associated via death domain
Caspase 4, apoptosis-related cysteine protease
Nuclear factor of kappa light polypeptide gene enhancer
Secreted frizzled-related protein 1
Presenilin 1 (Alzheimer disease 3)
Tumor protein p53 (Li-Fraumeni syndrome)
Tumor necrosis factor receptor superfamily, member 6b
v-akt murine thymoma viral oncogene homolog 1
Pleiomorphic adenoma gene-like 1
Islet amyloid polypeptide
Immediate early response 3
Somatostatin
v-raf murine sarcoma viral oncogene homolog B1
Protein tyrosine kinase 2 beta
Requiem, apoptosis response zinc finger gene
Harakiri, BCL2 interacting protein
v-raf murine sarcoma viral oncogene homolog B1
Tumor suppressing subtransferable candidate 3
v-rel reticuloendotheliosis viral oncogene homolog A
v-rel reticuloendotheliosis viral oncogene homolog A
Growth arrest-specific 2
Huntingtin (Huntington disease)
Death-associated protein kinase 2
APG12 autophagy 12-like (S. cerevisiae)
Progammed cell death 1
T
1
0
T
9
T
7
T
1
1
T
2
T
9
T
1
T
8
N
4
N
1
N
2
N
3Molecular Cancer 2005, 4:9 http://www.molecular-cancer.com/content/4/1/9
Page 7 of 16
(page number not for citation purposes)
Table 4: Genes significantly increased in tumors.
GeneBank 
Accession
Gene Symbol Normal 
Mean
Tumor 
Mean
Fold 
Change
P value
Cell Growth/Cycle
X16323 hepatocyte growth factor HGF 11 116 10.77 0.003305
AB017642 oxidative-stress responsive 1 OSR1 58 428 7.41 0.000819
AL078641 phorbolin-like protein APOBEC3G 15 92 6.21 0.000158
L17128 gamma-glutamyl carboxylase GGCX 64 346 5.37 0.000018
D21089 xeroderma pigmentosum, complementation group C XPC 292 1278 4.38 0.000284
AL050223 vesicle-associated membrane protein 2 VAMP2 360 1533 4.26 0.002196
D38145 prostaglandin I2 synthase PTGIS 29 121 4.09 0.000448
AF092563 structural maintenance of chromosomes 2-like 1 SMC2L1 58 185 3.21 0.002352
AF006087 actin related protein 2/3 complex, subunit 4 ARPC4 292 865 2.96 0.000565
AC004537 inhibitor of growth family, member 3 ING3 46 114 2.47 0.003976
AF013168 tuberous sclerosis 1 TSC1 35 86 2.45 0.001232
AJ236876 ADP-ribosyltransferase polymerase)-like 2 ADPRTL2 32 76 2.34 0.003874
Cell Death/Apoptosis
D38435 postmeiotic segregation increased 2-like PMS2L1 74 193 2.6 0.002976
M61906 phosphoinositide-3-kinase, regulatory subunit PIK3R1 43 104 2.4 0.004387
Signal Transduction
U26710 Cas-Br-M ectropic retroviral transforming sequence b CBLB 21 177 8.4 0.000082
AB010414 guanine nucleotide binding protein, gamma 7 GNG7 59 334 5.68 0.003835
U59913 mothers against decapentaplegic homolog 5 MADH5 14 73 5.22 0.004731
AB004922 Homo sapiens gene for Smad 3 MADH3 93 443 4.76 0.001024
L11672 zinc finger protein 91 ZNF91 428 2007 4.69 0.000376
D14838 fibroblast growth factor 9 FGF9 27 108 3.97 0.000752
W27899 member RAS oncogene family RAB6B 68 232 3.43 0.00501
U48251 protein kinase C binding protein 1 PRKCBP1 40 127 3.18 0.001999
U90268 cerebral cavernous malformations 1 CCM1 53 151 2.87 0.004392
AL050275 cysteine rich with EGF-like domains CRELD1 195 543 2.79 0.000828
AB014600 SIN3 homolog B, transcriptional regulator SIN3B 177 425 2.39 0.001924
M27691 cAMP responsive element binding protein 1 CREB1 107 229 2.15 0.003559
U85245 phosphatidylinositol-4-phosphate 5-kinase, type II, 
beta
PIP5K2B 244 518 2.12 0.000441
W25793 ring finger protein 3 RNF3 163 326 2 0.004947
Nucleic Acid Binding
D50912 RNA binding motif protein 10 RBM10 96 443 4.6 0.001925
U41315 makorin, ring finger protein, 4 MKRN4 404 808 2 0.000262
Ligand Binding
X67155 kinesin-like 5 KIF23 64 368 5.76 0.001584
AB028985 ATP-binding cassette, sub-family A, member 2 ABC1 65 262 4.04 0.001234
Z48482 matrix metalloproteinase 15 MMP15 139 495 3.56 0.003946
Enzyme
X13794 lactate dehydrogenase B LDHB 396 1606 4.05 0.000845
X15334 creatine kinase, brain CKB 939 2083 2.22 0.002008
X60708 dipeptidylpeptidase IV DPP4 133 291 2.19 0.000697
AC004381 SA homolog SAH 283 599 2.11 0.000168
AF000416 exostoses-like 2 EXTL2 134 271 2.02 0.001314
Embryogenesis
U48437 amyloid beta precursor-like protein 1 APLP1 851 2433 2.86 0.001043
U66406 ephrin-B3 EFNB3 168 438 2.6 0.00309
D50840 UDP-glucose ceramide glucosyltransferase UGCG 85 211 2.5 0.002554
Other/Unknown
L48215 hemoglobin, beta HBB 12 2099 178.78 0.001299
J00153 hemoglobin, alpha 1 HBA1 15 1249 82.25 0.001889
U30521 P311 protein C5orf13 157 453 2.88 0.001431
AB011169 similar to S. cerevisiae SSM4 TEB4 140 300 2.15 0.00154
AL031432 GCIP-interacting protein P29 99 198 2 0.002036Molecular Cancer 2005, 4:9 http://www.molecular-cancer.com/content/4/1/9
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tissue. In the case of the normal islets used as controls,
microscopic examination showed that greater than 90%
of the tissue was islet. Any contaminants would probably
have the effect of reducing the discriminant power to dif-
ferentiate tumor from normal. Thus, t-test p values and
fold changes would tend to under-represented and some,
otherwise significant, genes might be missed. The actual
data, represented by the hierarchical specimen clustering
(Figure 3), showed strong differential gene expression
relating to group identity as would be expected if the
overall gene expression levels were accurate. All the nor-
mals clustered together, separate from all the tumors.
Within the normals, the two male specimens clustered in
one group, and the two female in another. All the normal
Table 5: Genes significantly decreased in tumors.
GeneBank 
Accession
Gene Description Symbol Normal 
Mean
Tumor 
Mean
Fold 
Change
P value
Cell Growth/Division
D17291 regenerating protein I beta REG1B 6286 13 -499.46 0.000095
X67318 carboxypeptidase A1 CPA1 3928 121 -32.57 0.003205
AI763065 regenerating islet-derived 1 alpha REG1A 5641 334 -16.88 0.000001
D29990 solute carrier family 7, member 2 SLC7A2 2988 445 -6.72 0.002204
AB017430 kinesin-like 4 KIFF22 1223 316 -3.87 0.000177
Z25884 chloride channel 1 CLCN1 2511 655 -3.84 0.00013
X81438 amphiphysin AMPH 2686 752 -3.57 0.000002
L03785 myosin, light polypeptide 5 MYL5 207 59 -3.51 0.000233
W28062 guanine nucleotide-exch. Prot. 2 ARFGEF2 66 19 -3.46 0.003602
X52486 uracil-DNA glycosylase 2 UNG2 2555 756 -3.38 0.000514
M81933 cell division cycle 25A CDC25A 312 96 -3.25 0.000005
M69136 chymase 1 CMA1 360 115 -3.13 0.004413
U90543 butyrophilin BTN2A1 685 226 -3.04 0.000023
X69086 utrophin UTRN 1325 457 -2.90 0.000011
AF039241 histone deacetylase 5 HDAC5 1124 393 -2.86 0.000319
U49392 allograft inflammatory factor 1 AIF1 165 58 -2.82 0.000105
U81992 pleiomorphic adenoma gene-like 1 PLAGL1 330 118 -2.80 0.004717
L26336 heat shock 70kD protein 2 HSPA2 90 32 -2.79 0.000689
F27891 cytochrome c oxidase subunit VIa COX6A2 872 313 -2.79 0.000342
D87673 heat shock transcription factor 4 HSF4 1964 721 -2.73 0.000453
X97795 RAD54-like RAD54L 392 144 -2.72 0.001345
X92689 UDP-N-acetyl-alpha-D-galactosamine GALNT3 80 32 -2.50 0.000243
Y08683 carnitine palmitoyltransferase I CPT1B 1038 420 -2.47 0.000573
U40622 X-ray repair complementing defective repair 4 XRCC4 177 72 -2.45 0.000678
U64315 excision repair, complementation group 4 ERCC4 2122 868 -2.44 0.000045
AB020337 beta 1,3-galactosyltransferase B3GALT5 1489 635 -2.34 0.002613
U40152 origin recognition complex ORC1L 3671 1702 -2.16 0.001425
M10943 metallothionein 1F MT1F 5691 2653 -2.14 0.001707
X79882 major vault protein MVP 758 376 -2.02 0.001719
AF035960 transglutaminase 5 TGM5 3097 1542 -2.01 0.002951
Cell Death/Apoptosis
S81914 immediate early response 3 IER3 2209 480 -4.60 0.000307
D80007 programmed cell death 11 PDCD11 457 129 -3.55 0.002358
AF013956 chromobox homolog 4 CBX4 1599 492 -3.25 0.00034
U33284 protein tyrosine kinase 2 beta PTK2B 693 237 -2.93 0.000763
U90919 likely partner of ARF1 APA1 2687 1021 -2.63 0.000015
X57110 Cas-Br-M retroviral transforming CBL 1889 784 -2.41 0.000033
AL050161 pro-oncosis receptor PORIMIN 1178 497 -2.37 0.00031
U40380 presenilin 1 PSEN1 1301 569 -2.29 0.00012
D83699 harakiri, BCL2 interacting protein HRK 768 338 -2.27 0.001321
U07563 v-abl viral oncogene homolog 1 ABL1 1415 631 -2.24 0.000248
M95712 v-raf oncogene homolog B1 BRAF 338 157 -2.16 0.004207
M16441 lymphotoxin alpha LTA 2106 985 -2.14 0.000239
AF035444 pleckstrin homology-like domain, family A, member 2 PHLDA2 334 166 -2.01 0.001759Molecular Cancer 2005, 4:9 http://www.molecular-cancer.com/content/4/1/9
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islet preparations, which are composed predominantly of
beta cells, clustered closer to the insulinoma tumors than
to the other neuroendocrine tumor types. The gene clus-
tering results revealed 19 apoptosis-related genes whose
expression was suppressed in the islet tumors relative to
the normals. This suggests that apoptosis may play a sig-
nificant role in the development of these tumors.
One might have expected more variation in the gene
expression levels in the tumors than in the normal islets,
since tumors are often heterogonous. However the data
on the average CV of the genes in the normal and tumor
groups suggested that there was no more variation in the
tumors (average CV of 30%) than in the normals (average
CV of 31%). The low CV in the tumors may relate to the
Table 6: Genes significantly decreased in tumors (continued).
GeneBank 
Accession
Gene Description Symbol Normal 
Mean
Tumor 
Mean
Fold 
Change
P value
Signal Transduction
J00306 somatostatin SST 7701 284 -27.09 0
AI636761 somatostatin SST 7224 598 -12.09 0.000001
AB011143 GRB2-associated binding protein 2 GAB2 2237 402 -5.57 0.001816
M93056 serine (or cysteine) proteinase inhibitor SERPINB1 505 105 -4.80 0.004637
X68830 islet amyloid polypeptide IAPP 2231 477 -4.68 0.001221
AB029014 RAB6 interacting protein 1 RAB6IP1 824 181 -4.56 0.000155
AI198311 neuropeptide Y NPY 610 154 -3.96 0.004817
M28210 member RAS oncogene family RAB3A 2566 672 -3.82 0.000048
J04040 glucagon GCG 8620 2351 -3.67 0.000396
AF030335 purinergic receptor P2Y P2RY11 2314 680 -3.40 0.000058
M29335 major histocompatibility complex HLA-DOA 906 268 -3.39 0.00159
L38517 Indian hedgehog homolog IHH 3013 897 -3.36 0.000055
U95367 gamma-aminobutyric acid A receptor, pi GABRP 668 202 -3.30 0.000837
W28558 pleiotropic regulator 1 PLRG1 704 216 -3.26 0.000068
L08485 gamma-aminobutyric acid A receptor, alpha 5 GABRA5 342 107 -3.20 0.000336
AF004231 leukocyte immunoglobulin-like receptor LILRB2 93 30 -3.08 0.001105
AF055033 insulin-like growth factor binding protein 5 IGFBP5 126 43 -2.96 0.000257
AJ010119 ribosomal protein S6 kinase RPS6KA4 1532 522 -2.94 0.000201
U46194 Human renal cell carcinoma antigen RAGE 2057 754 -2.73 0.000324
L13858 son of sevenless homolog 2 SOS2 964 354 -2.72 0.000268
Z29572 tumor necrosis factor receptor superfamily TNFRSF17 184 68 -2.69 0.000178
U01134 fms-related tyrosine kinase 1 FLT1 910 379 -2.40 0.003257
D78156 RAS p21 protein activator 2 RASA2 327 144 -2.26 0.002332
U77783 glutamate receptor GRIN2D 518 240 -2.15 0.001379
D49394 5-hydroxytryptamine receptor 3A HTR3A 197 98 -2.02 0.002493
Nucleic Acid Binding
Z30425 nuclear receptor subfamily 1, group I, member 3 NR1I3 1008 356 -2.83 0.000329
U18760 nuclear factor I/X NFIX 5796 2216 -2.62 0.000711
AI223140 purine-rich element binding protein A PURA 1137 506 -2.25 0.002448
AF015950 telomerase reverse transcriptase TERT 561 255 -2.20 0.002839
U40462 zinc finger protein, subfamily 1A, 1 ZNFN1A1 662 308 -2.15 0.001171
Z93930 X-box binding protein 1 XBP1 2223 1061 -2.09 0.000277
AB019410 PET112-like PET112A 1422 707 -2.01 0.001309
Ligand Binding
X00129 retinol binding protein 4, plasma RBP4 1517 68 -22.27 0.004809
AJ223317 sarcosine dehydrogenase SARDH 3844 1069 -3.60 0.000085
AB017494 LCAT-like lysophospholipase LYPLA3 906 326 -2.78 0.001131
U78735 ATP-binding cassette, sub-family A, member 3 ABCA3 1914 706 -2.71 0.000288
AF026488 spectrin, beta, non-erythrocytic 2 SPTBN2 1604 671 -2.39 0.00005
U83659 ATP-binding cassette, sub-family C, member 3 ABCC3 1287 551 -2.34 0.00244
R93527 metallothionein 1H MT1H 5093 2196 -2.32 0.002937
AA586894 S100 calcium binding protein A7 S100A7 507 221 -2.29 0.000537
U91329 kinesin family member 1C KIF1C 2981 1484 -2.01 0.000518Molecular Cancer 2005, 4:9 http://www.molecular-cancer.com/content/4/1/9
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single mode of tumor formation (induction by the loss of
the menin tumor suppressor). However, there was
increased variation noted when the tumors and normals
were combined (Figure 2). This was probably the result of
the differences in expression between the tumors and the
normals.
Of particular interest was the high proportion (3/8) of
tumors expressing principally PP hormonal RNA. This
was entirely consistent with pathological studies showing
the preponderance of PP containing tumors in the
pancreas of MEN1 patients [31]. The fact that the clinical
classification of two patients (9 and 11) was different than
indicated by the hormone expression profile of the tumor
analyzed was a consequence of the facts that those
patients had multiple tumors secreting multiple hor-
mones but only insulin and gastrin and sometime PP over
secretion are likely to result in a clinical diagnosis.
The use of the Students t-test for comparison of multiple
genes might be questioned because the test was designed
for comparison of only two groups. In this study, we
confirmed that comparison of 923 genes would not gen-
erate an excess number of false positive results. Neverthe-
less, in the group of 193 genes finally selected at a p < =
.005, we can expect that 1 of those genes is a false positive.
This study suggests that the overall effect of loss of func-
tion of menin is the suppression of gene expression.
Nevertheless, there were 86 genes that were over-
expressed in the tumors relative to the normals. Although
we associate tumorigenesis with increased rates of growth,
Table 7: Genes significantly decreased in tumors (continued).
GeneChip 
Accession
Gene Description Symbol Normal 
Mean
Tumor 
Mean
Fold 
Change
P value
Enzyme
M81057 carboxypeptidase B1 CPB1 4534 79 -57.09 0.001106
X71345 protease, serine, 4 PRSS3 3859 76 -51.11 0.004102
X01683 serine (or cysteine) proteinase inhibitor, clade A SERPINA1 2550 74 -34.64 0.004833
M24400 chymotrypsinogen B1 CTRB1 5158 207 -24.95 0.001744
M18700 elastase 3A, pancreatic ELA3A 7058 384 -18.37 0.000009
U66061 protease, serine, 1 PRSS1 7291 645 -11.31 0.000047
L22524 matrix metalloproteinase 7 MMP7 595 54 -11.03 0.002591
AI655458 5-oxoprolinase (ATP-hydrolysing) OPLAH 446 99 -4.52 0.004072
H94881 FXYD domain-containing ion transport regulator 2 FXYD2 3116 708 -4.40 0.000539
AL021026 flavin containing monooxygenase 2 FMO2 905 215 -4.21 0.000804
AC005525 plasminogen activator, urokinase receptor PLAUR 1779 566 -3.14 0.000031
U40370 phosphodiesterase 1A, calmodulin-dependent PDE1A 268 89 -3.03 0.004023
R90942 sialyltransferase 7D SIAT7D 3148 1052 -2.99 0.002319
M84472 hydroxysteroid (17-beta) dehydrogenase 1 HSD17B1 1196 440 -2.72 0.000991
X55988 ribonuclease, RNase A family, 2 RNASE2 480 203 -2.36 0.001314
AB003151 carbonyl reductase 1 CBR1 4538 1945 -2.33 0.000511
X08020 glutathione S-transferase M1 GSTM1 2766 1376 -2.01 0.000519
Embryogenesis
U15979 delta-like homolog SIGLEC5 3384 402 -8.41 0.002927
M60094 H1 histone family, member T HIST1H1T 976 230 -4.23 0.001639
U50330 bone morphogenetic protein 1 BMP1 3298 973 -3.39 0.001637
M74297 homeo box A4 HOXA4 501 176 -2.85 0.000477
AJ011785 sine oculis homeobox homolog 6 SIX6 530 190 -2.79 0.000286
U66198 fibroblast growth factor 13 FGF13 191 73 -2.61 0.001068
D31897 double C2-like domains, alpha DOC2A 1151 451 -2.55 0.000068
U12472 glutathione S-transferase pi GSTP1 3122 1524 -2.05 0.000237
Transcription
AL049228 pleckstrin homology domain interacting protein PHIP 257 33 -7.69 0.000782
M27878 zinc finger protein 84 ZNF84 54 15 -3.64 0.001108
U77629 achaete-scute complex-like 2 ASCL2 438 184 -2.38 0.000058
D50495 transcription elongation factor A, 2 TCEA2 1330 595 -2.23 0.000019
U49857 transcriptional activator of the c-fos promoter CROC4 542 259 -2.09 0.003894Molecular Cancer 2005, 4:9 http://www.molecular-cancer.com/content/4/1/9
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Table 8: Genes significantly decreased in tumors (continued).
GeneBank 
Accession
Gene Description Symbol Normal 
Mean
Tumor 
Mean
Fold 
Change
P value
Other/Undefined
X72475 immunoglobulin kappa constant IGKC 1409 276 -5.11 0.000111
D17570 zona pellucida binding protein ZPBP 355 71 -5.02 0.001107
M90657 transmembrane 4 superfamily member 1 TM4SF1 592 141 -4.20 0.004537
AF063308 mitotic spindle coiled-coil related protein SPAG5 2015 502 -4.01 0.000588
U66059 T cell receptor beta locus TRB@ 3022 779 -3.88 0.000266
AL022165 carbohydrate sulfotransferase 7 CHST7 359 94 -3.82 0.001738
U10694 melanoma antigen, family A, 9 MAGEA9 1039 272 -3.82 0.000067
M73255 vascular cell adhesion molecule 1 VCAM1 80 22 -3.66 0.004179
U47926 leprecan-like 2 protein LEPREL2 1003 319 -3.15 0.00013
L05424 CD44 antigen CD44 1439 471 -3.05 0.001361
AI445461 transmembrane 4 superfamily member 1 TM4SF1 463 161 -2.88 0.002911
AF010310 proline oxidase homolog PRODH 1194 421 -2.84 0.000005
AF000991 testis-specific transcript, Y-linked 2 TTTY2 700 254 -2.76 0.000542
X57522 transporter 1, ATP-binding cassette, sub-family B TAP1 781 287 -2.72 0.000971
AA314825 trefoil factor 1 TFF1 1657 616 -2.69 0.000011
AB020880 squamous cell carcinoma antigen SART3 3228 1224 -2.64 0.000135
AF040707 homologous to yeast nitrogen permease NPR2L 1131 437 -2.59 0.001537
U47292 trefoil factor 2 TFF2 359 141 -2.54 0.000684
X69398 CD47 antigen CD47 350 144 -2.42 0.000853
U27331 fucosyltransferase 6 FUT6 1105 473 -2.34 0.000872
AI827730 cyclin M2 CNNM2 5863 2535 -2.31 0.000484
U05255 glycophorin B GYPB 1606 717 -2.24 0.00013
M34428 pvt-1 oncogene homolog, MYC activator PVT1 1231 550 -2.24 0.004423
U86759 netrin 2-like NTN2L 2039 937 -2.18 0.000204
D90278 CEA-related cell adhesion molecule 3 CEACAM3 4388 2024 -2.17 0.000902
L40400 ZAP3 protein ZAP3 1549 719 -2.15 0.000776
U48224 beaded filament structural protein 2, phakinin BFSP2 568 271 -2.10 0.000166
AI138834 deltex homolog 2 DTX2 311 148 -2.10 0.000687
M13755 interferon-stimulated protein, 15 kDa G1P2 1507 741 -2.03 0.001157
X52228 mucin 1, transmembrane MUC1 1523 756 -2.02 0.001707
Table 9: Correlation of GeneChip expression with quantitative RT-PCR.
Gene Symbol Correlation Probe Set Exons Gene Size (bp) Fold Change (T/N) P value GeneChip T vs. N
IER3 0.964 1237_at 1 1236 -4.6 0.0000
SST 0.925 37782_at 2 351 -12 0.0000
PHLDA2 0.909 40237_at 2 913 -2.01 0.0003
REG1B 0.875 35981_at 6 773 -499 0.0000
IAPP 0.823 37871_at 3 1462 -4.68 0.0033
REG1A 0.814 38646_s_at 6 808 -16.9 0.0000
FGF9 0.74 1616_at 3 1420 3.97 0.0031
CBLB 0.327 514_at 21 3923 3.01 0.0009
XPC 0.318 1873_at 16 3658 4.38 0.0018
HRK 0.273 34011_at 2 716 -2.27 0.0011
PTK2B 0.235 2009_at 38 4715 -2.94 0.0019
Average 0.655Molecular Cancer 2005, 4:9 http://www.molecular-cancer.com/content/4/1/9
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only two of eleven Cell Cycle and Cell Proliferation genes
were increased in the tumors. Since tumor growth may
also be significantly affected by rates of cell death, it is per-
haps significant that there were no Cell Death genes sig-
nificantly increased in the tumors relative to the controls.
The correlation of GeneChip results with quantitative
real-time PCR (Q-PCR, Table 9) was relatively good. How-
ever, there were some genes that correlated poorly (corre-
lation coefficient less than 0.6). Interestingly, most of the
genes with poor correlation coefficients had a large
number of exons, whereas those with high correlation
coefficients had a low number of exons. Since exhaustive
testing of alternative primer pairs for Q-PCR was not
made, it is possible that correlation coefficients of some
genes could be improved by the use of other primers.
Four studies of global gene expression in pancreatic islets
have been published recently [32-35]. Cardozo et al [32]
have used microarrays to look for NF-kB dependent genes
in primary cultures of rat pancreatic islets. Shalev et al [33]
have measured global gene expression in purified human
islets in tissue culture under high and low glucose concen-
trations. They noted that the TGFβ superfamily member
PDF was down regulated 10-fold in the presence of glu-
cose, whereas other TGFβ superfamily members were up
regulated. In the current study, none of the TGFβ super-
family members were significantly different between
tumor and normal. Scearce et al [34] have used a
The expression levels of 4 apoptosis-related genes are shown by GeneChip and quantitative RT-PCR: a) IER3; b) IAPP; c) SST;  d) PHLDA2 Figure 5
The expression levels of 4 apoptosis-related genes are shown by GeneChip and quantitative RT-PCR: a) IER3; b) IAPP; c) SST; 
d) PHLDA2. Normals (N) and tumors (T) are shown. Solid bars represent GeneChip and open bars represent Q-PCR results.
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pancreas-specific micro-chip, the PanChip to analyze gene
expression patterns in E14 to adult mice. Only a few spe-
cific genes were noted in the paper, and none of them had
human homologs of significance to the current study.
Maitra et al [35] conducted a study which in many ways
was similar to the current one. They compared gene
expression, using the Affymetrix U133A chip, in a series of
sporadic pancreatic endocrine tumors with isolated nor-
mal islets. There was no overlap in the genes they
identified (having a three-fold or greater difference in
expression) with the genes we identified (having a two-
fold or greater difference in expression). This is quite
surprising, but perhaps suggests that sporadically arising
tumors may have a quite different pattern of gene expres-
sion than tumors arising as a result of menin loss or dys-
function. Another possible cause of the differences may be
the different Affymetrix GeneChips used in the two
studies.
The question of which (if any) of the genes delineated in
this study are a direct and necessary affect of loss-of-
menin tumorigenesis cannot be determined by this study
alone. Firstly, the activity of many genes are regulated
both by their levels of expression and by post-translation
modifications, such as phosphorylation. Secondly, the
microchips used in this study represent only about 1/3 of
the total number of human genes. Thirdly, it is not certain
that the initiating gene changes caused by loss-of-menin
are persistent in the tumors that develop. However, there
were some genes, which because of their association with
growth or apoptosis are of special interest. The general
suppression of apoptosis related genes noted in this study
(Figure 4) has been highlighted by the recent study of
Schnepp et al, [36] who showed a loss of menin suppres-
sion of apoptosis in murine embryonic fibroblasts
through a caspase-8 mechanism. Specific apoptosis-
related genes which were suppressed in the tumors in the
current study, and which were confirmed by Q-PCR
include IER3, SST, PHLDA2, and IAPP. IER3 (IEX-1) is reg-
ulated by several transcription factors and may have posi-
tive or negative effects upon cell growth and apoptosis
depending upon the cell-specific context [37]. Several
studies have shown that it can be a promoter of apoptosis
[38-40]. Somatostatin has shown a wide range of growth
inhibitory activity in vitro and in vivo [41-57].PHLDA2
(TSSC3) is an imprinted gene homologous to the
murineTDAG51 apoptosis-related gene [58], and may be
involved in human brain tumors [59]. IAPP (amylin) is a
gene which has contrasting activities and has been associ-
ated with experimental diabetes in rodents [60]. Amylin
deposits were increased in islets of patients with gastrec-
tomy-induced islet atrophy [61]. On the other hand,
exposure of rat embryonic islets to amylin results in beta
cell proliferation [62]. In contrast, amylin has been shown
to induce apoptosis in rat and human insulinoma cells in
vitro [63,64]. In contrast to the suppression of apoptosis-
related genes, FGF9 (Figure 6), a growth promoting gene,
was significantly increased in the neuroendocrine tumors.
This protein has been reported to play roles in glial cell
growth [65], chondrocyte growth [66], prostate growth
[67], endometrial growth [68], and has been suggested to
have a role in human oncogenesis [69].
A recent report by Busygina et al [70] suggested that loss
of menin can lead to hypermutability in a Drosophila
model for MEN1. The spectrum of mutation sensitivity
suggested that there was a defect in nucleotide excision
repair. Whether the defect was a direct or indirect effect of
menin loss was not stated. In the current study, there was
a 2.44-fold decrease, in the tumors, in the expression of
ERCC4 (Table 5), a gene involved in nucleotide excision
repair. In addition, XRCC4, a gene involved in double-
strand break repair, was also decreased in the tumors in
the current study.
Conclusion
This first study of global gene expression in neuroendo-
crine tumors arising in the pancreas of patients with the
MEN1 syndrome has identified many genes that are dif-
ferentially expressed, as compared with normal human
islet cells. A number of these genes are strongly over/
under expressed and are attractive candidates for further
investigation into the mechanisms by which menin loss
causes tumors in pancreatic islets. Of particular interest
was a group of 24 apoptosis-related genes that were
significantly differentially expressed (mostly underex-
FGF9 expression levels in tumors (T) and normals (N) by  GeneChip and quantitative RT-PCR Figure 6
FGF9 expression levels in tumors (T) and normals (N) by 
GeneChip and quantitative RT-PCR. Solid bars represent 
GeneChip and open bars represent Q-PCR results.
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pressed) in the group of neuroendocrine tumors. The
underexpression of these apoptosis-related genes may be
related to neoplastic development or progression in these
MEN1-related neuroendocrine tumors.
Methods
Human Tissue Specimens
Tumor specimens were obtained from patients with the
MEN1 syndrome who had undergone surgery for islet-cell
tumors of the pancreas. The specific germline mutations
in the menin tumor suppressor gene were identified and
previously reported [6] for each of the patients. Six of the
patients had frame-shift mutations and one had a non-
sense mutation. Informed consent was obtained in
advance, and tumor tissues not needed for pathological
analysis were snap frozen in liquid nitrogen, and kept fro-
zen at -70° prior to RNA extraction. Normal pancreatic
islets (which were originally intended for human transpl-
atation studies, but were not used) were isolated from
brain-dead donors by a collagenase procedure, as previ-
ously described [71], and were then frozen until used for
extraction of RNA. Human Studies Committee approval
from Washington University School of Medicine was
obtained for this study.
Isolation of RNA from Tissue Specimens
Approximately 50 mg of tissue was removed from each
frozen tumor specimen and homogenized with a mortar
and pestle (Qiagen, Qiashredder Kit), and RNA was
extracted using the Rneasy Mini Kit (Qiagen, Inc.), and
quantified by UV absorbance. RNA was similarly isolated
from the normal human islet preparations.
GeneChip Hybridization and Analysis
The RNA was submitted to the GeneChip facility of the
Siteman Cancer Center at Washington University School
of Medicine. There, biotin labeled cRNA was prepared and
hybridized to U95Av2 microarray chips (Affymetrix). The
fluorescence of individual spots was then measured and
the data returned on compact discs. We analyzed the gene
expression data and made comparisons between groups
using the dChip computer program [30]. Following nor-
malization (to equalize the overall intensity of each chip),
the expression of each gene was determined by statistical
modeling procedure in the dChip software. Each gene was
represented by an array of 10 perfect match oligonucle-
otide spots and 10 mismatch oligonucleotide spots on the
U95Av2 chip. The dChip program examines all the spots
on all the chips involved in the study, and by a statistical
procedure determines single and array outliers. These out-
liers can be considered as "bad" readings, and removed
from further consideration.
Quantitative RT-PCR
The same preparations of total RNA that were used to
probe the GeneChips were also used to prepare c-DNA for
quantitative RT-PCR analysis of gene expression. C-DNA
was first prepared using Superscript II reverse transcriptase
(Invitrogen, Inc.). Primers for each gene were designed to
produce products of 100 to 150 bp that spanned exon
boundaries (when possible). The primer pairs are shown
in table 10.
The Sybr Green technique on an Applied Biosystems
model GeneAmp 5700 instrument was utilized. Relative
quantitation using a standard c-DNA preparation from an
in vitro islet tumor cell line was utilized.
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Table 10: 
Gene Forward Primer Reverse Primer
CBLB cacgtctaaatctatagcagccagaac tgcactcccaagcctcttctc
FGF9 cggcaccagaaattcacaca aaattgtctttgtcaactttggcttag
HRK agctggttcccgttttcca cagtcccattctgtgtttctacgat
IAPP ctgctttgtatccatgagggttt gaggtttgctgaaagccacttaa
ER3 ccagcatctcaactccgtctgt caccctaaaggcgacttcaaga
SST cccagactccgtcagtttctg tacttggccagttcctgcttc
PHLDA2 tgcccattgcaaataaatcact ctgcccgcccattcct
PTK2B gtgaggagtgcaagaggcagat gccagattggccagaacct
REG1A cctcaagcacaggattccaga acatgtattttccagctgcctcta
REG1B gggtccctggtctcctacaagt catttcttgaatcctgagcatgaa
XPC gcccgcaagctggacat atcagtcacgggatgggagtaMolecular Cancer 2005, 4:9 http://www.molecular-cancer.com/content/4/1/9
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